Navigation Links
Dyskinesia in Medical News

Reglan Adverse Events More Than Doubled from 2006 to 2008

... System reveals that new cases of tardive dyskinesia or other movement disorders reported by users of ... about the strong connection between tardive dyskinesia and the long-term use of Reglan. ... System reveals that new cases of tardive dyskinesia or other movement disorders reported by users of ...

Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Users

... has identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users ... or its generic version, metoclopramide. Tardive dyskinesia is a neurological disorder characterized by ... has identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users ...

$1.3M NIH grant to fund Parkinson's disease study

... hospital in Chicago hope to find a way to reduce dyskinesia and suppress these movements. There are very few treatments available, in part because how dyskinesia develops is still a mystery. "We are beginning to believe that dyskinesia is actually the inability to suppress motor ...

New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia

... should be stopped if the person being treated has NMS. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with ... and treatment of any concomitant serious medical problems. Tardive dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, ...

FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder

... should be stopped if the person being treated has NMS. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with ... and treatment of any concomitant serious medical problems. Tardive dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, ...

Parkinson's Treatment Drugs Even Out Over Long Term

... in Parkinson's patients but is also associated with side effects such as dyskinesia (involuntary movements), and the effectiveness of the drug can wear off ... levodopa were more likely to develop motor control complications such as dyskinesia and wearing off, but these complications didn't have a significant impact ...

Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels

... prescribing should be consistent with the need to minimize Tardive dyskinesia (TD). The risk of developing TD and the likelihood that it will become ... prescribing should be consistent with the need to minimize Tardive dyskinesia (TD). The risk of developing TD and the likelihood that it will become ...

FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... abnormality, contact your doctor IMMEDIATELY if you feel faint or feel a change in the way that your heart beats (palpitations). Tardive dyskinesia (TD) is a rare, but serious and sometimes permanent side effect reported with INVEGA(R) SUSTENNA(TM) and similar medicines. Call your doctor right ...

INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder

... increased heart rate or blood pressure, or muscle pain or weakness. Treatment should be stopped if you are being treated for NMS. Tardive dyskinesia (TD) is a rare, but serious and sometimes permanent side effect reported with INVEGA(R) and similar medicines. Call your doctor right away if you ...

Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development

... Symptomatic Approaches/Complications of Treatment Effect of novel neuronal nicotonic receptor compounds on treatment of levodopa-induced dyskinesia in Parkinson's disease Kristen Jordan, PhD, Targacept, Winston-Salem, North Carolina Optimization of MOR antagonists for the treatment ...
Dyskinesia in Medical Technology

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... should be stopped if the person being treated has NMS. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with ... and treatment of any concomitant serious medical problems. Tardive dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... abnormality, contact your doctor IMMEDIATELY if you feel faint or feel a change in the way that your heart beats (palpitations). Tardive dyskinesia (TD) is a rare, but serious and sometimes permanent side effect reported with INVEGA((R)) SUSTENNA(TM) and similar medicines. Call your doctor right ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... receive regular monitoring of weight. As with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... clinically important differences were observed between lurasidone and placebo for EPS (assessed using the Simpson-Angus Scale) or symptoms of tardive dyskinesia (assessed using the Abnormal Involuntary Movements Scale). There was a modest but significant worsening at endpoint in akathisia symptoms (assessed ...

New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

... advanced PD, the most commonly reported side effects of pramipexole that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), ...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

... interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable movements of the ...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

... treatment to their levodopa therapy. The primary efficacy endpoint of the study was the increase in mean daily "ON" time ("ON" time without dyskinesia plus "ON" time with minor dyskinesia) during an 18-hour period as assessed by patients' recordings on diary cards. Out of the 669 randomized ...

Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials

... . A Randomized, Placebo-controlled, Multiple Crossover (n-of-1), Pilot trial of Simvastatin on the Treatment of Levodopa-induced dyskinesia in Parkinson's Disease Patients Erwan Bezard, PhD, Universiy of Bordeaux, France, and Francois Tison, MD, PhD, Head of Movement Disorder Unit, ...

FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults

... and acute renal failure. Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the ...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

... in dyskinesias. Preladenant was found to be safe and well tolerated. The most common adverse events reported in this trial were parkinsonism, dyskinesia and somnolence, which occurred with approximately the same frequency in the preladenant arms as in the control group. "We are very excited ...

More>>

Dyskinesia in Medical Products

Activa Therapy System

Description:... treatment option for many Parkinson's patients. Activa Therapy controls rigidity, bradykinesia/akinesia and/or tremor while reducing the duration of dyskinesia related to antiparkinsonian ....
Company:Medtronic Inc.
Dyskinesia in Medical Dictionary

Tardive dyskinesia

... Tardive dyskinesia Definition: Tardive dyskinesia are involuntary movement s, especially of the ... of medications known as neuroleptics. Tardive dyskinesia is a movement disorder that occurs as a side ...
Dyskinesia in Biological Technology

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

... in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL(R) CONSTA(R) and similar medications. TD includes uncontrollable movements ...

Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia

... interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable movements of the ...

Lilly to Take Charge to Earnings Related to Pending Federal and State Investigations of Past Practices

... and acute renal failure. Also, as with all antipsychotic treatments, prescribing should be consistent with the need to minimize Tardive dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the ...

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

... should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is < 1000/mm.(3) Tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of ...

Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources

... medications interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable movements of the ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder

... (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs. Tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

... or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation is recommended Tardive dyskinesia (TD)-The risk of developing TD and the potential for it to become irreversible may increase as the duration of treatment and the total cumulative ...

Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress

... in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS. Tardive dyskinesia (TD) is a serious, sometimes permanent side effect reported with INVEGA and similar medications. TD includes uncontrollable movements of the face, ...
Dyskinesia in Biological Definition

Cilium

... transition zone which is less studied. A defect in the cilium can cause human disease. The best known cilia-related disorder is Primary Ciliary dyskinesia (PCD). In addition, a defect of the primary cilium in the renal tube cells can lead to polycystic kidney disease (PKD). In another genetic ...
Other Contents
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Dale ... the United States, will speak at the International Cannabis Professionals Expo held at the ... , The International Cannabis Professionals Expo is the largest medical cannabis ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... 30, 2015 , ... OSF Healthcare System has been recognized as ... Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive year for ... The Sisters of the Third Order of St. Francis . , Health data security ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca ... on the go. With no water needed, the refreshing berry-flavored tablets are the ... to get the natural ingredients that may help with body detoxification, protection and ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, ... than 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
Other TagsOther Tags